A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination
In recent years, combined therapy shows expected treatment effect as they increase dose intensity, work on multiple targets and benefit more patients for antitumor treatment. However, dose -finding designs for combined therapy face a number of challenges. Therefore, under the framework of phase I-II, we propose a two-stage dose -finding design to identify the biologically optimal dose combination (BODC), defined as the one with the maximum posterior mean utility under acceptable safety. We model the probabilities of toxicity and efficacy by using linear logistic regression models and conduct Bayesian model selection (BMS) procedure to define the most likely pattern of dose-response surface. The BMS can adaptively select the most suitable model during the trial, making the results robust. We investigated the operating characteristics of the proposed design through simulation studies under various practical scenarios and showed that the proposed design is robust and performed well.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of biopharmaceutical statistics - (2023) vom: 17. Juli, Seite 1-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Ziqing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive design |
|---|
| Anmerkungen: |
Date Revised 18.07.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/10543406.2023.2236208 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35961857X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35961857X | ||
| 003 | DE-627 | ||
| 005 | 20231226081248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10543406.2023.2236208 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM35961857X | ||
| 035 | |a (NLM)37461311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Ziqing |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a In recent years, combined therapy shows expected treatment effect as they increase dose intensity, work on multiple targets and benefit more patients for antitumor treatment. However, dose -finding designs for combined therapy face a number of challenges. Therefore, under the framework of phase I-II, we propose a two-stage dose -finding design to identify the biologically optimal dose combination (BODC), defined as the one with the maximum posterior mean utility under acceptable safety. We model the probabilities of toxicity and efficacy by using linear logistic regression models and conduct Bayesian model selection (BMS) procedure to define the most likely pattern of dose-response surface. The BMS can adaptively select the most suitable model during the trial, making the results robust. We investigated the operating characteristics of the proposed design through simulation studies under various practical scenarios and showed that the proposed design is robust and performed well | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bayesian model selection | |
| 650 | 4 | |a Phase I–II clinical trial | |
| 650 | 4 | |a adaptive design | |
| 650 | 4 | |a drug combination | |
| 650 | 4 | |a utility function | |
| 700 | 1 | |a Zhang, Jingyi |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a He, Ruyue |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Fangrong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biopharmaceutical statistics |d 1991 |g (2023) vom: 17. Juli, Seite 1-14 |w (DE-627)NLM012811432 |x 1520-5711 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:07 |g pages:1-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10543406.2023.2236208 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 07 |h 1-14 | ||